Company Logo
US NY Suffolk County Shirley Pharmaceutical Information

Semaglutide

Pharmaceutical Information

Updated on Apr 19, 2019

View more like this | Visit SHIRLEY, NY | Contact BOC Smith
Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. On Oct 18, 2017, Novo Nordisk received positive 16-0 vote from FDA Advisory Committee in favor of approval for Semaglutide
Image for Semaglutide with ID of: 3389649
View all posts by BOC SmithIs this your business? Claim this post.Contact BOC Smith
goodideazs, LLC is not affiliated with the authors of this post nor is it responsible for its content, the accuracy and authenticity of which should be independently verified.